Bioceres Crop Solutions Statistics
Total Valuation
BIOX has a market cap or net worth of $26.27 million. The enterprise value is $251.87 million.
Important Dates
The last earnings date was Monday, May 11, 2026, after market close.
| Earnings Date | May 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BIOX has 63.48 million shares outstanding. The number of shares has increased by 1.55% in one year.
| Current Share Class | 63.48M |
| Shares Outstanding | 63.48M |
| Shares Change (YoY) | +1.55% |
| Shares Change (QoQ) | +0.20% |
| Owned by Insiders (%) | 1.31% |
| Owned by Institutions (%) | 9.24% |
| Float | 43.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.10 |
| Forward PS | n/a |
| PB Ratio | 0.39 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.99 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.88, with a Debt / Equity ratio of 2.51.
| Current Ratio | 0.88 |
| Quick Ratio | 0.55 |
| Debt / Equity | 2.51 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -0.28 |
Financial Efficiency
Return on equity (ROE) is -32.22% and return on invested capital (ROIC) is -2.81%.
| Return on Equity (ROE) | -32.22% |
| Return on Assets (ROA) | -0.87% |
| Return on Invested Capital (ROIC) | -2.81% |
| Return on Capital Employed (ROCE) | -3.97% |
| Weighted Average Cost of Capital (WACC) | 10.41% |
| Revenue Per Employee | $339,824 |
| Profits Per Employee | -$329,233 |
| Employee Count | 751 |
| Asset Turnover | 0.38 |
| Inventory Turnover | 2.21 |
Taxes
In the past 12 months, BIOX has paid $8.33 million in taxes.
| Income Tax | 8.33M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -90.70% in the last 52 weeks. The beta is 0.39, so BIOX's price volatility has been lower than the market average.
| Beta (5Y) | 0.39 |
| 52-Week Price Change | -90.70% |
| 50-Day Moving Average | 0.49 |
| 200-Day Moving Average | 1.30 |
| Relative Strength Index (RSI) | 41.39 |
| Average Volume (20 Days) | 294,516 |
Short Selling Information
The latest short interest is 728,454, so 1.15% of the outstanding shares have been sold short.
| Short Interest | 728,454 |
| Short Previous Month | 934,995 |
| Short % of Shares Out | 1.15% |
| Short % of Float | 1.67% |
| Short Ratio (days to cover) | 1.88 |
Income Statement
In the last 12 months, BIOX had revenue of $255.21 million and -$247.25 million in losses. Loss per share was -$3.88.
| Revenue | 255.21M |
| Gross Profit | 93.42M |
| Operating Income | -9.21M |
| Pretax Income | -62.64M |
| Net Income | -247.25M |
| EBITDA | -3.90M |
| EBIT | -9.21M |
| Loss Per Share | -$3.88 |
Full Income StatementBalance Sheet
The company has $14.40 million in cash and $240.00 million in debt, with a net cash position of -$225.60 million or -$3.55 per share.
| Cash & Cash Equivalents | 14.40M |
| Total Debt | 240.00M |
| Net Cash | -225.60M |
| Net Cash Per Share | -$3.55 |
| Equity (Book Value) | 95.60M |
| Book Value Per Share | 1.06 |
| Working Capital | -36.80M |
Full Balance SheetCash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 5.32M |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
Gross margin is 36.60%, with operating and profit margins of -3.61% and -96.88%.
| Gross Margin | 36.60% |
| Operating Margin | -3.61% |
| Pretax Margin | -24.55% |
| Profit Margin | -96.88% |
| EBITDA Margin | -1.53% |
| EBIT Margin | -3.61% |
| FCF Margin | n/a |
Dividends & Yields
BIOX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.55% |
| Shareholder Yield | -1.55% |
| Earnings Yield | -941.06% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for BIOX is $2.00, which is 383.21% higher than the current price. The consensus rating is "Hold".
| Price Target | $2.00 |
| Price Target Difference | 383.21% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
